REGENXBIO to Announce Interim Clinical Trial Results

Maryland-based REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Biotech, as an industry, is expensive and requires lots of capital to support any development and innovation. Earlier this month, REGENXBIO announced a partnership with AbbVie. Now, we can expect a presentation of some of their data from their RGX-314 clinical trials. The partnership with AbbVie allowed REGENXBIO to unlock the full value of its organic pipeline.

They will present their data at the Retina Society 54th Annual Scientific Meeting in Illinois. Their product, RGX-314, is a potential best-in-class, one-time gene therapy for the treatment of wet AMD. The presentation will show interim results at six months of follow up for patients in Cohort 1 (dose level: 2.5×1011 genome copies per eye)

RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the accumulation of fluid in the retina.

REGENXBIO is advancing research in two separate routes of administration of RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. REGENXBIO has licensed certain exclusive rights to the SCS Microinjector® from Clearside Biomedical, Inc. to deliver gene therapy treatments to the suprachoroidal space of the eye.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts